≥99% purity peptides, distributed from Hong Kong and shipped across Southeast Asia. Science you can trust, wherever you're based.
Research protocols built for expats across Southeast Asia. One trusted source.
TRIUMPH-1 (May 2026): 28.3% mean body weight reduction at 80 weeks — the largest Phase 3 obesity result ever published, beating Tirzepatide by 5.8 points and Semaglutide by 13.4 points. At 104 weeks: 30.3%. TRIUMPH-4 (December 2025): 28.7% at 68 weeks plus 75.8% reduction in knee pain.
This is why Paradise Peptides stocks Retatrutide and not Semaglutide. Seven additional TRIUMPH Phase 3 readouts expected across 2026 covering obesity, type 2 diabetes, cardiovascular disease and sleep apnoea.
Read the full research →Free peptide reconstitution calculator. Built for precision, works offline, installs as an app.
Open Calculator →